Champions Oncology (CSBR)
Provides oncology research services, patient-derived models, testing platforms, and data offerings for biopharma.
CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push
Champions Oncology reports fourth-quarter fiscal 2026 growth as revenue gains, margin improvement and operational initiatives support progress.
Champions Oncology, Inc. (CSBR) Q4 2026 Earnings Call Transcript
Champions Oncology, Inc. (CSBR) Q4 2026 Earnings Call Transcript
Champions Oncology Q4 Earnings Call Highlights
Champions Oncology NASDAQ: CSBR reported record revenue for fiscal 2026 and positive adjusted EBITDA in every quarter of the year, supported by growth in its core Translational Oncology Solutions, or TOS, services business and efforts to bring radiopharmaceutical work in-house.
Champions Oncology Reports Record Annual Revenue of $59 Million
Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA HACKENSACK, NJ / ACCESS Newswire / July 27, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncology research models and translational solutions, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2026. Fourth Quarter and Other Financial Highlights: Record annual revenue of $59.4 million Fourth quarter revenue of $13.8 million Fourth quarter oncology services margin of 51% Adjusted EBITDA of $158,000 for the quarter and $1.6 million for the fiscal year Adjusted EBITDA income all four quarters in FY 2026 Continued investment in radiopharmaceuticals, the data platform and commercial organization Robert Brainin, CEO of Champions, commented, "Fiscal 2026 marked a year of meaningful progress in executing our strategic priorities as we delivered record annual revenue while continuing to invest in the capabilities we believe will support our next phase of growth.
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which life sciences stock offers better long-term upside? Let's dive in.
2 Microcaps With Gross Margin Catalysts
CSBR and CEPL have levers in place for Gross Margin improvement.
Zacks Initiates Coverage of Champions Oncology With Neutral Recommendation
Discover why Zacks rates Champions Oncology as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore CSBR's accelerating pharmacology services and expanding data initiatives amid execution risks and commercialization timing.
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 27, 2026
HACKENSACK, NJ / ACCESS Newswire / July 20, 2026 / Champions Oncology, Inc. (NASDAQ:CSBR), a global leader in clinically relevant oncology research models and translational solutions, will report its financial and operational results for the quarter and year ended April 30, 2026, on Monday, July 27, 2026, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
Champions Oncology (NASDAQ:CSBR) Share Price Passes Below Two Hundred Day Moving Average – Time to Sell?
Champions Oncology, Inc. (NASDAQ: CSBR - Get Free Report) shares passed below its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $6.48 and traded as low as $5.85. Champions Oncology shares last traded at $6.04, with a volume of 5,373 shares trading hands. Wall
Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026
Eight studies demonstrate how clinically relevant models and integrated data can reduce translational risk and guide development decisions HACKENSACK, NJ / ACCESS Newswire / April 9, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncology research models and translational solutions, today announced it will present new data across eight poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 2026, in San Diego, California. The presentations will highlight research across key areas of oncology drug development, including KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, antibody-drug conjugates (ADCs), and CAR-T therapies.
Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy
Appointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&D HACKENSACK, NJ / ACCESS Newswire / March 30, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced the appointment of Brian Alexander, MD, MPH, to its Board of Directors. Dr. Alexander brings extensive experience at the intersection of oncology, data science, and drug development, having held senior leadership roles at organizations including Valo Health, Flagship Pioneering, and Foundation Medicine.
Champions Oncology, Inc. (CSBR) Q3 2026 Earnings Call Transcript
Champions Oncology, Inc. (CSBR) Q3 2026 Earnings Call Transcript
Champions Oncology Reports Revenue of $16.6 Million
Company remains on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the fiscal year HACKENSACK, NJ / ACCESS Newswire / March 12, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its third quarter of fiscal 2026, ended January 31, 2026. Third Quarter and Recent Highlights: Record study service revenue of $16.6 million, up approximately 32% year over year Total revenue of $16.6 million, compared to $17.0 million in the prior-year period Adjusted EBITDA of $574,000; GAAP loss from operations of approximately $276,000 The Company's third quarter reflected record service revenue driven by strong study execution and the conversion of previously booked work.
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026
HACKENSACK, NJ / ACCESS Newswire / March 5, 2026 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for the third quarter ended January 31, 2026, on Thursday, March 12, 2026, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call Transcript
Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call Transcript
Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million
We remain on track to deliver year-over-year revenue growth and to generate positive adjusted EBITDA for the fiscal year HACKENSACK, NJ / ACCESS Newswire / December 15, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its second quarter of fiscal 2026, ended October 31, 2025. Second Quarter and Recent Highlights: Total revenue increased 11% to $15 million Oncology services profit of $7.8 million; oncology services margin of 52% Net income of $237,000 Adjusted EBITDA of $843,000 First Half 2026 Highlights: Total revenue increased 5% to $29 million Oncology services profit of $13.8 million; oncology services margin of 47% Adjusted EBITDA of $962,000 Robert Brainin, CEO of Champions, commented, "Our recent results reinforced our confidence in the Company's ongoing return to growth, as we continued to make progress.
Champions Oncology to Announce Second Quarter Financial Results on Monday, December 15, 2025
HACKENSACK, NJ / ACCESS Newswire / December 8, 2025 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for the second quarter ended October 31, 2025, on Monday, December 15, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
Champions Oncology, Inc. (CSBR) Q1 2026 Earnings Call Transcript
Champions Oncology, Inc. (NASDAQ:CSBR ) Q1 2026 Earnings Call September 15, 2025 4:30 PM EDT Company Participants Robert Brainin - CEO & Director David Miller - Chief Financial Officer Conference Call Participants George Marema - Pareto Ventures Tollef Kohrman - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Greetings. Welcome to the Champions Oncology First Quarter Fiscal Year 2026 Earnings Call.
CORRECTION: Champions Oncology Reports Quarterly Revenue of $14.0 Million
This release contains a headline correction from the previous publication. Positive start to FY 2026 with steady revenue, data growth and new leadership HACKENSACK, NJ / ACCESS Newswire / September 15, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its first quarter of fiscal 2026, ended July 31, 2025.
Champions Oncology to Announce First Quarter Financial Results on Monday, September 15, 2025
HACKENSACK, NJ / ACCESS Newswire / September 10, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the quarter ended July 31, 2025, on Monday, September 15, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.